Work

A phase Ib study evaluating the safety and tolerability of durvalumab in combination with eribulin in patients with HER2-negative metastatic breast cancer and recurrent ovarian cancer.

Year: 2018

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2018.36.15_suppl.tps3116

Authors: Chrystal Ann Landry, Jeannette Marcelle Guziel, Meng Ru, Charles L. Shapiro, Julie Fasano, Aarti Sonia Bhardwaj, Hanna Irie, Nina Bhardwaj, Amy Tiersten

Institutions: Icahn School of Medicine at Mount Sinai, Kaiser Permanente, Tisch Cancer Institute

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2889797227

Cites:

Cited by: 3

Related to: 10